New ODC guidelines align industrial hemp and medicinal cannabis industries

New ODC guidelines align industrial hemp and medicinal cannabis industries

In one of my old blogs, Cultivation of Medicinal Cannabis vs Hemp, I highlighted the differences between the industrial hemp and medicinal cannabis industries – in particular, the fact that there was little-to-no crossover between the two (other than industrial hemp businesses being able to supply seeds to the medicinal cannabis industry). However, Professor John…

ODC updates from the Australian Medicinal Cannabis Conference 2020

ODC updates from the Australian Medicinal Cannabis Conference 2020

This year due to COVID, the Australian Medicinal Cannabis Conference 2020 is being hosted virtually, and we have had many generous presenters come on board to share valuable information and experience. For those who are mainly concerned about the ODC regulatory updates (doctors and patient access topics excluded) I’ve summarised the main points from Adj…

PIC/S GMPs vs WHO GMPs – what’s the difference?
|

PIC/S GMPs vs WHO GMPs – what’s the difference?

t]As many are aware, the Pharmaceutical Inspection Co-operation Scheme (PIC/S) develops and provides standards and guidelines for the harmonisation of Good Manufacturing Practice(GMP) in the global pharmaceutical industry. Those who fall under the umbrella of participating countries, often take for granted the fact that PIC/S is the go-to for compliance (i.e. Part 1, Part 2…

Impact of COVID-19 on Pharmaceutical Manufacturing
|

Impact of COVID-19 on Pharmaceutical Manufacturing

How is the pharmaceutical manufacturing industry around the world expected to continue production during the COVID-19 pandemic? What control measures should be in place to help prevent or mitigate the potential adverse effects of COVID-19 on the safety and quality of products? In April 2020, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published…